Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This Phase 2 study was intended to demonstrate superiority of sotagliflozin versus placebo on Hemoglobin A1C (A1C) reduction at Week 12 in young adult participants with type 1 diabetes mellitus (T1DM) who have poor glycemic control on their current insulin regimen.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lexicon Pharmaceuticals
• Collaborators: Juvenile Diabetes Research Foundation; Sanofi
• Treatments: (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol

Criteria

Inclusion Criteria:

• Participant had given written informed consent.

• Young adult participants >=18 to <=30 years old at Screening, with a confirmed diagnosis of T1DM made at least 1 year prior to informed consent.

• Participants were being treated with insulin or insulin analogue delivered via continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).

• At Screening, must had A1C >= 9.0%.

• Must be willing and able to perform self-monitored blood glucose (SMBG) and complete the study diary.

• Females of childbearing potential must use an adequate method of contraception and had a negative pregnancy test.

Exclusion Criteria:

• Any prior use of LX4211/sotagliflozin.

• Use of antidiabetic agent other than insulin or insulin analogue at the time of screening.

• Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to start of the placebo Run-in Period.

• Chronic systemic corticosteroid use.

• Type 2 diabetes, or severely uncontrolled diabetes mellitus as determined by the Investigator.

• History of diabetic ketoacidosis (DKA) or nonketotic hyperosmolar state within 6 months prior to the Screening Visit.

• History of severe hypoglycemic event within 1 month prior to the Screening Visit.